$PRNB News
Last published 5y ago
- 5y agoPRNBPhase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis - NCT04992546ClinicalTrials.govAdverse events (AEs) and serious AEs, Assessment of local cutaneous tolerability, Plasma PRN473 concentrations
- 5y agoPRNBPatient Enrollment Concluded Early in PEGASUS Phase 3 Pemphigus Trial for RilzabrutinibGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc., a Sanofi company, focused on developing treatments for immune mediated diseases, today announced it has...
- 6y agoPRNBPh3 Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) - NCT04562766ClinicalTrials.govSustained Increase in Platelet Counts (Efficacy Outcome Measure), Incidence of Treatment Emergent Adverse Events (Safety Outcome Measure)
- 6y agoPRNBPrincipia Announces First Patient Dosed in Phase 2A Trial of Rilzabrutinib in IgG4-Related DiseaseGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated...
- 6y agoVARPFNXSBPHPRNBMoore Kuehn Encourages SBPH, PFNX, VAR, and PRNB Investors to Contact Law FirmGlobeNewswireNEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning...
- 6y agoPRNBNew patent application published for: Immunoproteasome InhibitorsUS Patent Applications (USPTO)( 1 of 1 )
- 6y agoNTNPRNBMNTAPFNXMoore Kuehn Encourages NTN, PRNB, MNTA, and PFNX Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
- 6y agoPRNBOpen Label Two-Arm Study to Evaluate Rilzabrutinib (PRN1008) in IgG4-Related Disease Patients - NCT04520451ClinicalTrials.govThe proportion of patients who achieve complete remission at Week 12 with no glucocorticoid use at Week 4 for the Experimental Arm and Week 12 for the Active Comparator Arm., Serum IgG4 concentrations, IgG4-RD Responder Index
- 6y agoPRNBMNTAJNJJ&J to Buy Momenta for About $6.5 Billion for Autoimmune DrugsBloombergJohnson & Johnson agreed to buy Momenta Pharmaceuticals Inc. for about $6.5 billion to expand in treatments for autoimmune diseases.
- 6y agoPRNBSTOCKHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Principia Biopharma Inc. - PRNBPR NewswireJuan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in ...
- 6y agoABX-CAGMTDOCLEN+9Stocks making the biggest moves midday: Barrick Gold, Tesla, Teladoc, Home Depot & moreCNBCBarrick Gold gets a boost after Berkshire Hathaway discloses a stake in the company. Teladoc jumped on a Credit Suisse upgrade.
- 6y agoSAN-FRPRNBABX-CABRK.A+15Stocks making the biggest moves in the premarket: Sanofi, Barrick Gold, Nvidia, Home Depot & moreCNBCThe stocks making the biggest moves in premarket trading include
- 6y agoBACREGNGILDPRNBSanofi to Buy U.S. Autoimmune Drugmaker in $3.4 Billion DealBloombergSanofi plans to acquire San Francisco, California-based Principia Biopharma Inc in a deal with an enterprise value of $3.4 billion as the French drugmaker pivots toward innovative therapies to spur growth.The all-cash deal will see Sanofi taking full control of the American company which focuses on treatments for multiple sclerosis and a range of autoimmune disorders, the company said in a stateme ...
- 6y agoPRNBSNYSanofi to acquire Principia BiopharmaPR NewswireSanofi and Principia Biopharma Inc. (NASDAQ: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated...
- 6y agoPRNBPrincipia Biopharma Reports Second Quarter 2020 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated...
- 6y agoNFLXBLKRFMSFT+11Stocks making the biggest moves in the premarket: Netflix, BlackRock, Microsoft, Lyft & moreCNBCThe stocks making the biggest moves in premarket trading include Netflix, BlackRock, Microsoft, Lyft, and more.
- 6y agoBACREGNPRNBSanofi Considers U.S. Biotech Targets Including PrincipiaBloombergSanofi is studying potential acquisitions of U.S. biotechnology companies including Principia Biopharma Inc. as it seeks innovative treatments for clinical areas including multiple sclerosis and immune disorders, people with knowledge of the matter said.
- 6y agoPRNBPrincipia Announces First Patient Enrolled in Sanofi’s Phase 3 Trial of SAR442168 in Relapsing Multiple SclerosisGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated...
- 6y agoPRNBPrincipia Announces Positive Data from its Phase 2 Part B Trial in PemphigusGlobeNewswireClear dose-response combined with decreased daily corticosteroid usage Response rate increased with extended duration of treatment to six months while maintaining a favorable safety profile ...
- 6y agoPRNBPrincipia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase 1/2 TrialGlobeNewswireOral BTK inhibitor reaches primary endpoint in 50 percent of patients treated > 12 weeks; demonstrates fast onset and durable responses Principia to initiate pivotal Phase 3 trial in ITP ...
- 6y agoPRNBPrincipia Announces Data Presentations of Rilzabrutinib in Patients with Immune Thrombocytopenia (ITP) at Two Upcoming Virtual Medical MeetingsGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 26, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated...
- 6y agoPRNBPrincipia Announces AAD Late Breaker Research Presentation of its Pemphigus Phase 2 Part B TrialGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated...
- 6y agoJPMPRNBLLYTop Stock Picker Sees New Alignment With Covid-19Bloomberg“This time it’s different,” says Fidelity’s Eddie Yoon, who has outperformed his peers in health-care funds.
- 6y agoPRNBNew patent application published for: Treatment of PemphigusUS Patent Applications (USPTO)
- 6y agoPRNBPrincipia Biopharma Reports Fourth Quarter and Full Year 2019 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 10, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated...
- 6y agoPRNBPrincipia to Present at 9th Annual SVB Leerink Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune...
- 6y agoPRNBSahm Adrangi's Kerrisdale Capital Issues Negative Report on Principia Biopharma Inc. and Announces Conference Call SchedulePR NewswireKerrisdale Capital, a private investment manager, has published a report explaining its short position in Principia Biopharma Inc. (NASDAQ: PRNB), a...
- 6y agoPRNBPrincipia Announces Expansion of its BTK Franchise with PRN473 TopicalGlobeNewswireCompany expands focus on immune-mediated diseases and suspends FGFR program Company outlines anticipated key corporate milestones SOUTH SAN FRANCISCO, Calif., Jan. 09, 2020 (GLOBE...
- 6y agoPRNBPrincipia Announces Expanded Development Program to Broaden BTK Footprint in Immune-Mediated DiseasesGlobeNewswireCompany’s lead candidate PRN1008 receives generic name -- rilzabrutinib Rilzabrutinib to enter clinical trial in IgG4-Related Disease SOUTH SAN FRANCISCO, Calif., Jan. 07, 2020 (GLOBE...
- 6y agoPRNBPrincipia Updates PRN1008 Pemphigus Clinical ProgramGlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 30, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to...
- 6y agoPRNBPrincipia Presents Consistent Positive Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 TrialGlobeNewswireORLANDO, Fla., Dec. 07, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases,...
- 7y agoPRNBPrincipia to Present at the Stifel Healthcare Conference 2019GlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune...
- 7y agoPRNBPrincipia Biopharma Reports Third Quarter Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune...
- 7y agoPRNBPrincipia Announces Pricing of Public Offering of Common StockGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune...
- 7y agoPRNBPrincipia Announces Proposed Public Offering of Common StockGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune...
- 7y agoPRNBPrincipia Announces Positive Preliminary Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 TrialGlobeNewswireSOUTH SAN FRANCISCO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated...
- 7y agoPRNBPrincipia Announces Positive Preliminary Data of PRN1008 from its Ongoing Phase 2 Part B Trial in PemphigusGlobeNewswireConsistent efficacy and safety profile for pemphigus patients observed Confirms 400mg twice daily dose in Phase 3 trial Principia to host investor conference call at 8:00 am Eastern time SOUTH...
- 7y agoPRNBPrincipia Biopharma Appoints Shawn Tomasello to Its Board of DirectorsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to...
- 7y agoPRNBPrincipia to Present at the 2019 Baird Global Healthcare Conference and the Wells Fargo Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to...